Van Andel Research Institute (VARI) researchers have determined how two proteins mandatory for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved therapys for the disease. One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally identified for its role in the development of breast cancer. SCR3 has also been characterized as a key factor in the development of prostate cancer, but, until now, the exact relationship between androgen receptor and SCR3 has been unclear........
Medical News 
Creaform, a global provider of digitizing technologies, developed the Handyscan 3D line-up of laser scanners. These scanners allow the scanning of objects to generate digital files that can be modified and edited in various post-treatment software. Thanks to this state-of-the-art technology, it would be possible to create a well-adjusted, comfortable, and natural-looking prosthesis.
A new analysis has observed that a considerable proportion of patients with end-stage or terminal cancer do not benefit from palliative radiation treatment (radiotherapy) despite spending most of their remaining life undergoing therapys. Published early online in CANCER, a peer-evaluated journal of the American Cancer Society, the study indicates that greater efforts are needed to tailor appropriately palliative radiotherapy to patients with end-stage cancer........
